Table 2.
Demographic and clinical characteristic of CIS and RR-MS patients.
| Interferon-beta | GA | DF | |
|---|---|---|---|
| Variable | Value | Value | Value |
| Number | 116 | 51 | 59 |
| Duration of MS, years (mean ± SD) | 2.7 ± 5.6 | 2.7 ± 4.8 | 4.0 ± 6.8 |
| Gender | |||
| -male (n, %) | 41 (35.3) | 13 (25.5) | 18 (30.5) |
| -female (n, %) | 75 (64.7) | 38 (74.5) | 41 (69.5) |
| Age, years (mean ± SD) | 34.1 ± 11.1 | 38.1 ± 11.8 | 36.8 ± 12.9 |
| EDSS score (median, IQR) | 1.5 (1.0) | 2.0 (1.9) | 2.0 (1.8) |
| Unique CSF OCB | * | ** | *** |
| -positive (n, %) | 83 (73.5) | 39 (84.8) | 38 (66.7) |
| -negative (n, %) | 30 (26.5) | 7 (15.2) | 19 (33.3) |
| Previous number of relapses before LP (mean ± SD) | 1.6 ± 0.9 | 1.5 ± 0.9 | 1.4 ± 0.7 |
*
missing data for three patients (2.6%); **missing data for five patients (9.8%); ***missing data for two patients (3.4%).
CIS, clinically isolated syndrome; CSF, cerebrospinal fluid; DF, dimethyl fumarate; EDSS, expanded disability status scale; GA, glatiramer acetate; IQR, interquartile range; LP, lumbar puncture; MS, multiple sclerosis; OCB, oligoclonal bands; RR-MS, relapsing remitting multiple sclerosis; SD standard deviation.